JP2007217437A - カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法 - Google Patents
カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法 Download PDFInfo
- Publication number
- JP2007217437A JP2007217437A JP2007150243A JP2007150243A JP2007217437A JP 2007217437 A JP2007217437 A JP 2007217437A JP 2007150243 A JP2007150243 A JP 2007150243A JP 2007150243 A JP2007150243 A JP 2007150243A JP 2007217437 A JP2007217437 A JP 2007217437A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- potassium channel
- intraocular pressure
- potassium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 17
- 241000124008 Mammalia Species 0.000 title claims abstract description 13
- 230000004410 intraocular pressure Effects 0.000 title claims description 34
- 239000003450 potassium channel blocker Substances 0.000 title abstract description 14
- 229940125422 potassium channel blocker Drugs 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 102000004257 Potassium Channel Human genes 0.000 claims abstract description 18
- 108020001213 potassium channel Proteins 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 230000000903 blocking effect Effects 0.000 claims abstract description 11
- JDUWHZOLEDOQSR-JKPSMKLGSA-N Penitrem A Chemical compound O([C@H]1[C@H]2[C@@](C(N3)=C11)(C)[C@@]4(C)CC[C@@H]5O[C@@H]([C@@H]([C@H]6O[C@@]56[C@]4(O)CC2)O)C(=C)C)C(C)(C)[C@H]2C[C@H]4[C@]2(O)C2=C1C3=CC(Cl)=C2CC4=C JDUWHZOLEDOQSR-JKPSMKLGSA-N 0.000 claims abstract description 5
- VDNVVLOBNHIMQA-UHFFFAOYSA-N iberiotoxin Chemical compound C1SSCC(C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(O)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C1NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(C(C)C)NC(=O)CNC(=O)C(CC=1C=CC=CC=1)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CCCCN)NC1=O)CSSCC1NC(=O)C(C(C)C)NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)NC1=O)CSSCC1NC(=O)C(CC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(O)=O)NC(=O)C(C(C)O)NC(=O)C(NC(=O)C1NC(=O)CC1)CC1=CC=CC=C1 VDNVVLOBNHIMQA-UHFFFAOYSA-N 0.000 claims abstract description 5
- 108010068927 iberiotoxin Proteins 0.000 claims abstract description 5
- JDUWHZOLEDOQSR-UHFFFAOYSA-N penitrem A Natural products C1CC2(O)C34OC4C(O)C(C(=C)C)OC3CCC2(C)C(C(N2)=C34)(C)C1C3OC(C)(C)C1CC3C1(O)C1=C4C2=CC(Cl)=C1CC3=C JDUWHZOLEDOQSR-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229930005303 indole alkaloid Natural products 0.000 claims abstract description 4
- 150000002475 indoles Chemical class 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 25
- 239000002997 ophthalmic solution Substances 0.000 claims description 7
- 229940054534 ophthalmic solution Drugs 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 5
- 239000003889 eye drop Substances 0.000 claims description 5
- 206010044565 Tremor Diseases 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 abstract description 26
- 235000001258 Cinchona calisaya Nutrition 0.000 abstract description 13
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract description 13
- 229960000948 quinine Drugs 0.000 abstract description 13
- 208000010412 Glaucoma Diseases 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 11
- 206010030043 Ocular hypertension Diseases 0.000 abstract description 3
- 108010023798 Charybdotoxin Proteins 0.000 abstract description 2
- 241000238631 Hexapoda Species 0.000 abstract description 2
- HSFKQYJRJBEWKH-XTHGXZEWSA-N Paspalicine Chemical compound C1=CC=C2C(C[C@@H]3CC[C@@H]4[C@]([C@@]53C)(C)CC[C@]36OC([C@H](C(=O)C=C34)O6)(C)C)=C5NC2=C1 HSFKQYJRJBEWKH-XTHGXZEWSA-N 0.000 abstract description 2
- HSFKQYJRJBEWKH-UHFFFAOYSA-N Paspalicine Natural products C1=CC=C2C(CC3CCC4C(C53C)(C)CCC36OC(C(C(=O)C=C34)O6)(C)C)=C5NC2=C1 HSFKQYJRJBEWKH-UHFFFAOYSA-N 0.000 abstract description 2
- CNVQLPPZGABUCM-LIGYZCPXSA-N ctx toxin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@@H](C(N[C@@H](CC=4C5=CC=CC=C5NC=4)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3NC=NC=3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N2)C(C)C)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC1=O)=O)CCSC)C(C)C)[C@@H](C)O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 CNVQLPPZGABUCM-LIGYZCPXSA-N 0.000 abstract description 2
- 239000003053 toxin Substances 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 abstract description 2
- 108700012359 toxins Proteins 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 16
- 210000001742 aqueous humor Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 13
- 230000001886 ciliary effect Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 8
- 229910052700 potassium Inorganic materials 0.000 description 8
- 239000011591 potassium Substances 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000003204 osmotic effect Effects 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000037427 ion transport Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 210000001585 trabecular meshwork Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000001384 anti-glaucoma Effects 0.000 description 4
- 230000004509 aqueous humor production Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 229940097320 beta blocking agent Drugs 0.000 description 3
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- 239000003604 miotic agent Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 201000006366 primary open angle glaucoma Diseases 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WBSMIPAMAXNXFS-UHFFFAOYSA-N 5-Nitro-2-(3-phenylpropylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCCC1=CC=CC=C1 WBSMIPAMAXNXFS-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010062745 Chloride Channels Proteins 0.000 description 2
- 102000011045 Chloride Channels Human genes 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 2
- 239000000150 Sympathomimetic Substances 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- -1 amine salts Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960001416 pilocarpine Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940127230 sympathomimetic drug Drugs 0.000 description 2
- 229960004605 timolol Drugs 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- 241000237967 Aplysia Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000000030 antiglaucoma agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Eye Examination Apparatus (AREA)
Abstract
【解決手段】哺乳動物の緑内障および/または高眼圧を処置するための、薬剤組成物と、本発明の薬剤組成物を哺乳動物の眼に投与することによる方法とを開示する。本発明の薬剤組成物は、カリウムチャンネル遮断活性を有する化合物1種またはそれ以上を活性成分として含有する。本発明の薬剤組成物および処置方法において使用するカリウムチャンネル遮断剤の例は、キニーネ、振戦誘発性インドールアルカロイド、例えばペニトレムAおよびパスパリシン、並びに昆虫毒素、例えばカリブドトキシンおよびイベリオトキシンである。
【選択図】図2
Description
更に、PCT出願公開WO 89/10757には、カリウムチャンネル開放剤を緑内障処置に使用することが開示されている。
驚くべきことに、カリウムチャンネル遮断剤は、薬剤組成物(好ましくは局所的眼用組成物)として哺乳動物の眼に適用すると、抗緑内障剤として、および眼圧降下剤として有効であるということが、本発明によってわかった。すなわち、本発明は、有効量のカリウムチャンネル遮断剤を含有する眼用組成物を哺乳動物の眼に局所投与することによって、緑内障または高眼圧を処置する方法に関する。とりわけ、房水生成を抑制するためには(流入抑制)、無色素性毛様体上皮細胞(NPE)の基底外側膜に存在するカリウムチャンネルを遮断し得る。NPE細胞のカリウムチャンネルを遮断すると、正味溶質およびH2O流出(すなわち、房水分泌)を抑制し得、それによりIOPを降下し得ると考えられる。カリウムチャンネル遮断剤の好ましいいくつかの例は、キニーネ、振戦誘発性(tremogenic)インドールアルカロイド、例えばペニトレム(Penitrem)Aおよびパスパリシン(paspalicine)、並びに昆虫毒素、例えばカリブドトキシン(charybdotoxin)およびイベリオトキシン(iberiotoxin)である。とりわけ、振戦誘発性インドールアルカロイドが、NPE細胞のカリウムチャンネル遮断に特に有効であり得る。なぜなら、そのような化合物はCa2+依存性(Ca2+−gated)Maxiカリウムチャンネルを非常に特異的に遮断するからである:NPE細胞のカリウムチャンネルは、Ca2+依存性Maxiカリウムチャンネルであると見られる。このように、NPE細胞のカリウムチャンネル遮断によって、房水分泌を抑制し、それにより眼圧(IOP)を降下する。
本発明の方法に従って、および本発明の薬剤組成物中に使用する化合物は、カリウムチャンネル遮断剤である。ここで、「カリウムチャンネル遮断剤」は、生体膜のカリウム特異的通路(チャンネル、膜内在性タンパク質)からの正味カリウム移動(流動)を抑制する化合物または剤であると定義する。本発明に従って使用するカリウムチャンネル遮断剤の特定の好ましい例は前記の通りである。
カリウムチャンネル遮断剤は、以下の実施例に記載の方法に従って同定してもよい。
本発明を、インビトロおよびインビボのデータによって説明する。図1によると、ウシ無色素性毛様体上皮(NPE)細胞の低張膨潤の後に起こる調節体積減少(RVD)を、100μMのキニーネが抑制した。この例において、NPE細胞を低張(198mOsm)溶液に懸濁させる前に、100μMキニーネ含有等張(295mOsm)溶液に30分間懸濁させた。対照細胞は、同じ低張溶液で処理したが、媒体中にキニーネは加えなかった。コールター・チャンネライザー(Coulter Channelyzer)に接続したコールター・カウンターを用いて、細胞体積の変化を測定した。浸透圧的膨潤の後、対照細胞は元の等張体積を回復するが、キニーネ処理細胞は膨潤したままであることがわかる。上記知見は、キニーネは、カリウムチャンネルの遮断によって、溶質、および浸透圧に従うH2Oの流出を抑制することを示すものである。NPE細胞の浸透圧的膨潤後に活性化されるカリウム依存性イオン流出路は、房水分泌に関与するから、キニーネは房水生成を抑制し、それ故IOPを降下し得る。
以上の説明から、請求の範囲は開示に照らして理解されるので、本発明の範囲は請求の範囲にのみ基づいて解釈すべきであることが明らかである。
Claims (11)
- 哺乳動物の眼圧を降下するのに有用な薬剤組成物であって、活性成分として、Ca2+依存性Maxiカリウムチャンネルを非常に特異的に遮断する化合物から成る群から選択する化合物1種またはそれ以上を処置有効量で含有する薬剤組成物。
- カリウムチャンネル遮断活性を有する化合物はカリブドトキシンまたはイベリオトキシンである請求項1記載の薬剤組成物。
- 哺乳動物の眼に点眼剤として投与するのに適した眼用溶液である請求項1記載の薬剤組成物。
- カリウムチャンネル遮断活性を有する化合物を、0.0001〜1%(w/v)含有する請求項1記載の薬剤組成物。
- 前記化合物は、ペニトレムAおよびパスパリシンから成る群から選択する請求項1記載の薬剤組成物。
- 前記化合物は、振戦誘発性インドールアルカロイドから成る群から選択する請求項1記載の薬剤組成物。
- Ca2+依存性Maxiカリウムチャンネルの遮断によってヒトを包含する哺乳動物の眼圧を降下する目的で哺乳動物を処置する方法であって、活性成分として、ペニトレムA、パスパリシン、カリブドトキシンおよびイベリオトキシンから成る群から選択する化合物1種またはそれ以上を処置有効量で含有する薬剤組成物を哺乳動物に投与するステップを含んで成る方法。
- カリウムチャンネル遮断活性を有する化合物はカリブドトキシンである請求項7記載の方法。
- 前記組成物は、哺乳動物の眼に点眼剤として投与するのに適した眼用溶液である請求項7記載の方法。
- 前記組成物は、カリウムチャンネル遮断活性を有する化合物を、0.0001〜1%(w/v)含有する請求項7記載の方法。
- 前記化合物は、ペニトレムAおよびパスパリシンから成る群から選択する請求項7記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/431,170 US5573758A (en) | 1995-04-28 | 1995-04-28 | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8532585A Division JPH11504330A (ja) | 1995-04-28 | 1996-04-16 | カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007217437A true JP2007217437A (ja) | 2007-08-30 |
Family
ID=23710776
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8532585A Withdrawn JPH11504330A (ja) | 1995-04-28 | 1996-04-16 | カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法 |
JP2007150243A Pending JP2007217437A (ja) | 1995-04-28 | 2007-06-06 | カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8532585A Withdrawn JPH11504330A (ja) | 1995-04-28 | 1996-04-16 | カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5573758A (ja) |
EP (2) | EP1243270B2 (ja) |
JP (2) | JPH11504330A (ja) |
AT (2) | ATE225658T1 (ja) |
AU (1) | AU703241B2 (ja) |
DE (2) | DE69624234D1 (ja) |
ES (2) | ES2204879T5 (ja) |
WO (1) | WO1996033719A1 (ja) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69634414T2 (de) | 1995-12-21 | 2005-11-17 | Alcon Laboratories, Inc., Fort Worth | Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie |
US5925342A (en) * | 1996-11-13 | 1999-07-20 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
AU771130B2 (en) * | 2000-01-18 | 2004-03-11 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
US6548535B2 (en) | 2000-01-18 | 2003-04-15 | Merck & Co., Inc. | Method for treating ocular hypertension |
EP1357855A2 (en) * | 2001-01-30 | 2003-11-05 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
DE60225420T2 (de) * | 2001-01-30 | 2009-03-26 | Merck & Co., Inc. | Verfahren zur identifizierung von maxi-k-kanal-blockern |
US20040115739A1 (en) * | 2002-01-25 | 2004-06-17 | Garcia Maria L | Method for identifying maxi-k channel blockers for use in lowering elevated intraocular pressure using hek-293 cells |
AU2003217810C9 (en) * | 2002-02-28 | 2008-06-12 | Icagen, Inc. | Methods for treating diseases related to intraocular pressure |
US7119112B2 (en) * | 2002-02-28 | 2006-10-10 | Icagen, Inc. | Sulfonamides as potassium channel blockers |
WO2003077845A2 (en) * | 2002-03-15 | 2003-09-25 | Merck & Co., Inc. | Compositions and methods for treating glaucoma and ocular hypertension |
WO2003105847A1 (en) * | 2002-06-14 | 2003-12-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
JP2005533055A (ja) * | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | 新規マキシkチャンネルブロッカー、その使用方法および製造方法 |
JP2005538061A (ja) * | 2002-06-17 | 2005-12-15 | メルク エンド カムパニー インコーポレーテッド | 新規maxi−kチャネルブロッカー、その使用方法および製造方法 |
EP1581503A4 (en) * | 2002-11-08 | 2007-07-25 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION |
US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7414067B2 (en) | 2003-03-27 | 2008-08-19 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
CA2530081A1 (en) * | 2003-07-01 | 2005-01-13 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
JP2007504228A (ja) * | 2003-09-02 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼組成物 |
CA2537430A1 (en) * | 2003-09-04 | 2005-03-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
JP4546961B2 (ja) * | 2003-09-04 | 2010-09-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 高眼圧の治療のための眼科用組成物 |
US20050250779A1 (en) * | 2004-05-04 | 2005-11-10 | Song Zhu | Pteridinone derivatives for treating ocular hypertension |
CA2574078A1 (en) | 2004-07-20 | 2006-02-23 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
JP2008515982A (ja) * | 2004-10-13 | 2008-05-15 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼科組成物 |
AU2005295997A1 (en) * | 2004-10-13 | 2006-04-27 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
JP2009533326A (ja) * | 2006-03-13 | 2009-09-17 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症の治療用眼科用組成物 |
EP2032130A4 (en) * | 2006-06-12 | 2011-03-02 | Merck Sharp & Dohme | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF EYE HIGH PRESSURE |
EP1941876A1 (en) * | 2006-12-28 | 2008-07-09 | Lacer, S.A. | Isosorbide mononitrate derivatives for the treatment of Inflammation and ocular hypertension |
EP2436387B1 (en) * | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
KR20140024914A (ko) | 2011-04-29 | 2014-03-03 | 셀진 코포레이션 | 예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법 |
ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
EP3160486B1 (en) | 2014-06-27 | 2020-11-18 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989010757A1 (en) * | 1988-05-10 | 1989-11-16 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis | New ophthalmic preparation for treating glaucoma |
EP0430621A3 (en) * | 1989-11-29 | 1992-03-04 | Beecham Group P.L.C. | Process for the preparation of chiral 3,4-epoxy benzopyrans |
US5512591A (en) * | 1993-02-18 | 1996-04-30 | President And Fellows Of Harvard College | Treatments for diseases characterized by neovascularization |
AU7099194A (en) * | 1993-06-08 | 1995-01-03 | Vide Pharmaceuticals | Methods and compositions for lowering intraocular pressure |
US5494895A (en) * | 1993-07-22 | 1996-02-27 | Merck & Co., Inc. | Scorpion peptide margatoxin with immunosuppressant activity |
GB9316111D0 (en) * | 1993-08-04 | 1993-09-22 | Pfizer Ltd | Benzopyrans |
-
1995
- 1995-04-28 US US08/431,170 patent/US5573758A/en not_active Expired - Lifetime
-
1996
- 1996-04-16 JP JP8532585A patent/JPH11504330A/ja not_active Withdrawn
- 1996-04-16 ES ES02009867T patent/ES2204879T5/es not_active Expired - Lifetime
- 1996-04-16 EP EP02009867A patent/EP1243270B2/en not_active Expired - Lifetime
- 1996-04-16 AT AT96912798T patent/ATE225658T1/de not_active IP Right Cessation
- 1996-04-16 AU AU55488/96A patent/AU703241B2/en not_active Ceased
- 1996-04-16 WO PCT/US1996/005241 patent/WO1996033719A1/en active IP Right Grant
- 1996-04-16 AT AT02009867T patent/ATE251458T1/de not_active IP Right Cessation
- 1996-04-16 EP EP96912798A patent/EP0825863B1/en not_active Expired - Lifetime
- 1996-04-16 DE DE69624234T patent/DE69624234D1/de not_active Expired - Lifetime
- 1996-04-16 ES ES96912798T patent/ES2182973T3/es not_active Expired - Lifetime
- 1996-04-16 DE DE69630325T patent/DE69630325T3/de not_active Expired - Lifetime
-
2007
- 2007-06-06 JP JP2007150243A patent/JP2007217437A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2204879T5 (es) | 2009-06-19 |
ATE225658T1 (de) | 2002-10-15 |
WO1996033719A1 (en) | 1996-10-31 |
ES2204879T3 (es) | 2004-05-01 |
AU703241B2 (en) | 1999-03-25 |
DE69630325D1 (de) | 2003-11-13 |
JPH11504330A (ja) | 1999-04-20 |
AU5548896A (en) | 1996-11-18 |
EP0825863A1 (en) | 1998-03-04 |
DE69630325T3 (de) | 2009-11-19 |
DE69630325T2 (de) | 2004-07-29 |
EP1243270B1 (en) | 2003-10-08 |
US5573758A (en) | 1996-11-12 |
EP1243270B2 (en) | 2009-03-25 |
ES2182973T3 (es) | 2003-03-16 |
EP1243270A1 (en) | 2002-09-25 |
EP0825863B1 (en) | 2002-10-09 |
DE69624234D1 (de) | 2002-11-14 |
ATE251458T1 (de) | 2003-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007217437A (ja) | カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法 | |
US5925342A (en) | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers | |
US4476140A (en) | Composition and method for treatment of glaucoma | |
US6376541B1 (en) | Upregulation of endogenous prostaglandins to lower intraocular pressure | |
JP4934653B2 (ja) | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 | |
EP0786994B1 (en) | Use of chloride channel blockers for reducing intraocular pressure | |
EP1541151A1 (en) | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS | |
TW202126308A (zh) | 青光眼治療劑與高眼壓症治療劑 | |
JP2004518612A (ja) | インドール誘導体を用いて眼圧を下降させる方法 | |
JP4482726B2 (ja) | Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 | |
JP2001508035A (ja) | 炭酸脱水酵素阻害薬及びキサンタンガムを含有する眼科用組成物 | |
JP2001521500A (ja) | 緑内障に関連する視神経変性を防止する薬剤の製造におけるナトリウムチャンネル遮断剤の使用 | |
BG64525B1 (bg) | Използване инхибиторите на карбоанхидразата за лечение на оток на макулата | |
US5578638A (en) | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists | |
JPH08511024A (ja) | 眼内圧を低下させる方法および組成物 | |
JP4300347B2 (ja) | ブナゾシンとプロスタグランジン類からなる緑内障治療剤 | |
US5563171A (en) | Treatment of glaucoma and ocular hypertension with β3-adrenergic agonists | |
CA2219280C (en) | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers | |
AU723823B2 (en) | Use of chloride channel blockers for providing a neuroprotective effect to the mammalian eye | |
KR20080068881A (ko) | 안압 강하제인 숙신이미드 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100706 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101006 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101012 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110104 |